Welcome to our dedicated page for DFP Holdings SEC filings (Ticker: DFPH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on DFP Holdings's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into DFP Holdings's regulatory disclosures and financial reporting.
Podnos Yale reported acquisition or exercise transactions in this Form 4 filing.
Oncology Institute, Inc. reported that its Chief Medical Officer, Yale Podnos, received a grant of 66,446 shares of common stock on March 27, 2026 at no cost as part of a restricted stock unit (RSU) award. According to the terms, one quarter of the RSUs vest on the first anniversary of the vesting commencement date, with the remaining portions vesting in three equal annual installments so that all units vest by the fourth anniversary, subject to continued service. The issuer also executed a sale of 16,173 shares at $3.07 per share to cover tax liabilities arising from the vesting of an RSU award on March 31, 2026, a mechanistic tax-related transaction rather than an open-market trade.
Podnos Yale reported acquisition or exercise transactions in this Form 4 filing.
Oncology Institute, Inc. reported that its Chief Medical Officer, Yale Podnos, received a grant of 66,446 shares of common stock on March 27, 2026 at no cost as part of a restricted stock unit (RSU) award. According to the terms, one quarter of the RSUs vest on the first anniversary of the vesting commencement date, with the remaining portions vesting in three equal annual installments so that all units vest by the fourth anniversary, subject to continued service. The issuer also executed a sale of 16,173 shares at $3.07 per share to cover tax liabilities arising from the vesting of an RSU award on March 31, 2026, a mechanistic tax-related transaction rather than an open-market trade.
Carter Robert Ross reported acquisition or exercise transactions in this Form 4 filing.
Oncology Institute, Inc. reported that Chief Financial Officer Robert Ross received a grant of 202,914 shares of common stock in the form of restricted stock unit (RSU) awards. The RSUs vest over four years, with one quarter vesting on the first anniversary of the vesting start date and the remainder in three equal annual installments, subject to continued service. The company also executed a sale of 20,320 shares at $3.07 per share to cover tax liabilities arising from an RSU vesting on March 31, 2026. Following these transactions, Ross directly holds 416,405 common shares.
Carter Robert Ross reported acquisition or exercise transactions in this Form 4 filing.
Oncology Institute, Inc. reported that Chief Financial Officer Robert Ross received a grant of 202,914 shares of common stock in the form of restricted stock unit (RSU) awards. The RSUs vest over four years, with one quarter vesting on the first anniversary of the vesting start date and the remainder in three equal annual installments, subject to continued service. The company also executed a sale of 20,320 shares at $3.07 per share to cover tax liabilities arising from an RSU vesting on March 31, 2026. Following these transactions, Ross directly holds 416,405 common shares.
Virnich Daniel reported acquisition or exercise transactions in this Form 4 filing.
Oncology Institute, Inc. CEO Daniel Virnich reported equity compensation activity. He received a grant of 670,608 shares of common stock as RSU awards at $0.00 per share, which vest over four years subject to continued service. Separately, the issuer executed a sale of 98,534 shares at $3.07 per share to cover tax liabilities arising from RSU vesting on March 31, 2026. After these transactions, Virnich directly holds 2,360,224 common shares.
Virnich Daniel reported acquisition or exercise transactions in this Form 4 filing.
Oncology Institute, Inc. CEO Daniel Virnich reported equity compensation activity. He received a grant of 670,608 shares of common stock as RSU awards at $0.00 per share, which vest over four years subject to continued service. Separately, the issuer executed a sale of 98,534 shares at $3.07 per share to cover tax liabilities arising from RSU vesting on March 31, 2026. After these transactions, Virnich directly holds 2,360,224 common shares.
Oncology Institute, Inc. disclosed that major shareholder Jorey Chernett, a more than ten percent owner, made an open-market purchase of 50,000 shares of common stock. The shares were bought at a weighted average price of $3.15 per share, with individual trade prices ranging from $3.11 to $3.19. Following this transaction, Chernett directly owns 10,451,929 shares of Oncology Institute common stock, indicating this buy added modestly to an already large position.
Oncology Institute, Inc. major shareholder Jorey Chernett reported an open-market purchase of 125,000 shares of common stock at a weighted average price of $3.11 per share. After this buy, Chernett directly owns 10,401,929 common shares. The purchase was executed in multiple trades between $3.04 and $3.15 per share.
Oncology Institute, Inc. ten percent owner Jorey Chernett bought 25,000 shares of Common Stock in an open‑market transaction. The weighted average purchase price was about $3.35 per share, with individual trades between $3.33 and $3.35.
After this purchase, Chernett directly owns 10,276,929 Oncology Institute shares.
Oncology Institute, Inc. ten percent owner Jorey Chernett bought 25,000 shares of Common Stock in an open‑market transaction. The weighted average purchase price was about $3.35 per share, with individual trades between $3.33 and $3.35.
After this purchase, Chernett directly owns 10,276,929 Oncology Institute shares.
Oncology Institute, Inc. director Kimberly Jo Tzoumakas filed an initial Form 3, which is a required statement of beneficial ownership when someone becomes an insider. This filing does not report any transactions or derivative positions and serves only to establish her reporting status with the company.
Oncology Institute, Inc. director Kimberly Jo Tzoumakas filed an initial Form 3, which is a required statement of beneficial ownership when someone becomes an insider. This filing does not report any transactions or derivative positions and serves only to establish her reporting status with the company.
Oncology Institute, Inc. Chief Executive Officer Daniel Virnich reported an administrative stock transaction linked to restricted stock unit (RSU) vesting. On March 17, 2026, the issuer executed a sale of 11,834 shares of common stock at $3.59 per share to cover tax liabilities from the RSU vesting. Following this tax-related sale, Virnich’s directly held position is 1,788,150 common shares, indicating he retains a large equity stake after the routine transaction.
Oncology Institute, Inc. Chief Financial Officer Robert Ross Carter reported an "other" type transaction involving 1,314 shares of common stock at $3.59 per share on March 17, 2026. According to the disclosure, the issuer executed the sale to cover tax liabilities arising from the vesting of a restricted stock unit (RSU) award on that date, making this a tax-related, non-discretionary event rather than an open-market trade. Following the transaction, Carter directly held 233,811 shares of common stock.
Oncology Institute, Inc. Chief Medical Officer Yale Podnos reported an administrative share transaction involving 3,420 shares of common stock on March 17, 2026 at $3.59 per share. According to the footnote, the issuer executed this sale to cover tax liabilities from the vesting of a restricted stock unit (RSU) award on the same date.
Following the transaction, Podnos directly holds 234,510 common shares. Because the sale was made to satisfy tax obligations tied to compensation vesting, it reflects a routine, non-discretionary event rather than an open-market investment decision.